NASDAQ:INM InMed Pharmaceuticals (INM) Stock Price, News & Analysis $2.98 +0.03 (+1.02%) As of 04/30/2025 03:30 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About InMed Pharmaceuticals Stock (NASDAQ:INM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get InMed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.87▼$2.9850-Day Range$1.87▼$3.0152-Week Range$1.72▼$15.70Volume4,109 shsAverage Volume229,014 shsMarket Capitalization$3.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewInMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Read More… InMed Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreINM MarketRank™: InMed Pharmaceuticals scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for InMed Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of InMed Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InMed Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInMed Pharmaceuticals has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about InMed Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.12% of the float of InMed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInMed Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InMed Pharmaceuticals has recently increased by 58.18%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInMed Pharmaceuticals does not currently pay a dividend.Dividend GrowthInMed Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.12% of the float of InMed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInMed Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InMed Pharmaceuticals has recently increased by 58.18%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.44 News SentimentInMed Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for InMed Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added InMed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InMed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.85% of the stock of InMed Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 20.12% of the stock of InMed Pharmaceuticals is held by institutions.Read more about InMed Pharmaceuticals' insider trading history. Receive INM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address INM Stock News HeadlinesInMed Pharmaceuticals Board Reshuffle After Director ResignationFebruary 14, 2025 | tipranks.comInMed Pharmaceuticals Second Quarter 2025 Earnings: US$3.65 loss per share (vs US$3.71 loss in 2Q 2024)February 14, 2025 | finance.yahoo.comHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.May 1, 2025 | Brownstone Research (Ad)InMed Pharmaceuticals: InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular DegenerationFebruary 3, 2025 | finanznachrichten.deInMed advances AMD treatment with promising IVT drug formulationFebruary 3, 2025 | msn.comInMed Pharmaceuticals announces INM-089 IVT formulation as drug candidateFebruary 3, 2025 | markets.businessinsider.comInMed Advances INM-089 for Dry AMD Treatment with New Intravitreal FormulationFebruary 3, 2025 | tipranks.comInMed announces ‘positive’ results from in vivo preclinical Alzheimer’s studyJanuary 22, 2025 | markets.businessinsider.comSee More Headlines INM Stock Analysis - Frequently Asked Questions How have INM shares performed this year? InMed Pharmaceuticals' stock was trading at $4.74 at the beginning of the year. Since then, INM stock has decreased by 37.1% and is now trading at $2.98. View the best growth stocks for 2025 here. How were InMed Pharmaceuticals' earnings last quarter? InMed Pharmaceuticals Inc. (NASDAQ:INM) posted its earnings results on Wednesday, February, 12th. The company reported ($3.64) EPS for the quarter. InMed Pharmaceuticals had a negative net margin of 163.75% and a negative trailing twelve-month return on equity of 90.74%. When did InMed Pharmaceuticals' stock split? Shares of InMed Pharmaceuticals reverse split on the morning of Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of InMed Pharmaceuticals? Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InMed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that InMed Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Tesla (TSLA) and PayPal (PYPL). Company Calendar Last Earnings2/12/2025Today4/30/2025Next Earnings (Estimated)5/13/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INM CIK1728328 Webwww.inmedpharma.com Phone604-669-7207FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($13.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,680,000.00 Net Margins-163.75% Pretax Margin-163.58% Return on Equity-90.74% Return on Assets-71.70% Debt Debt-to-Equity Ratio0.09 Current Ratio3.05 Quick Ratio2.44 Sales & Book Value Annual Sales$4.83 million Price / Sales0.74 Cash FlowN/A Price / Cash FlowN/A Book Value$5.12 per share Price / Book0.58Miscellaneous Outstanding Shares1,207,000Free Float711,000Market Cap$3.60 million OptionableNot Optionable Beta0.30 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:INM) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.